JonesResearch analyst Soumit Roy upgraded Beam Therapeutics (BEAM) to Buy from Hold with a $34 price target The company announced positive first-in-human in vivo editing data from its Phase 1/2 trial with BEAM-302 in alpha-1 antitrypsin deficiency, the analyst tells investors in a research note. Jones upped its probability of success for AATD to 35% from 15% and increased its adjusted peak sales to $1.9B in 2036. The firm believes BEAM-302 has the potential to be a one-time treatment for AATD. It thinks today’s data de-risks Beam’s platform “on multiple levels.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics upgraded to Buy from Hold at JonesResearch
- Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright
- Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target
- Beam Therapeutics upgraded to Outperform from Sector Perform at Scotiabank
- Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst
Questions or Comments about the article? Write to editor@tipranks.com